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Abstract 
Objectives: Our aim was to study the effect of combination therapy with aspirin and 
dipyridamole (A+D) over aspirin alone (ASA) in secondary prevention after transient 
ischemic attack or minor stroke of presumed arterial origin and to perform subgroup 
analyses to identify patients that might benefit most from secondary prevention with 
A+D. 
Data sources: The previously published meta-analysis of individual patient data was 
updated with data from ESPRIT (N=2,739); trials without data on the comparison of 
A+D versus ASA were excluded.  
Review methods: A meta-analysis was performed using Cox regression, including 
several subgroup analyses and following baseline risk stratification. 
Results: A total of 7,612 patients (5 trials) were included in the analyses, 3,800 allocated 
to A+D and 3,812 to ASA alone. The trial-adjusted hazard ratio for the composite event 
of vascular death, non-fatal myocardial infarction and non-fatal stroke was 0.82 (95% 
confidence interval 0.72-0.92). Hazard ratios did not differ in subgroup analyses based on 
age, sex, qualifying event, hypertension, diabetes, previous stroke, ischemic heart disease, 
aspirin dose, type of vessel disease and dipyridamole formulation, nor across baseline 
risk strata as assessed with two different risk scores. A+D were also more effective than 
ASA alone in preventing recurrent stroke, HR 0.78 (95% CI 0.68 – 0.90). 
Conclusion: The combination of aspirin and dipyridamole is more effective than aspirin 
alone in patients with TIA or ischemic stroke of presumed arterial origin in the secondary 
prevention of stroke and other vascular events. This superiority was found in all 
subgroups and was independent of baseline risk. 
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 Introduction 
After a transient ischemic attack (TIA) or stroke of presumed arterial origin patients have 
an annual risk of a serious vascular event (recurrent stroke, myocardial infarction or death 
from vascular cause) of 9% in population based studies.1 Treatment with aspirin, in a 
dose between 30 and 300 mg daily, reduces this risk by 13-22%.2-4 In one study, 
treatment with dipyridamole alone was found to reduce risk by a similar amount.5 
Although clopidogrel was marginally superior to aspirin in the CAPRIE trial, no 
statistically significant difference was seen in the subset of patients with previous 
ischemic stroke (average event rate per year 7.15% for clopidogrel versus 7.71% for 
aspirin, relative-risk reduction of 7.3% (95% CI -5.7-18.7).6 Furthermore, there is no 
indication for an additional benefit of combining aspirin and clopidogrel as compared 
with either drug alone,7;8 or for anticoagulation treatment with any INR range.9-13 The 
combination of aspirin and dipyridamole has been tested in several trials although early 
results did not show any beneficial effect over aspirin alone.14-17 In contrast, the ‘Second 
European Stroke Prevention Study’ (ESPS 2) found that the addition of dipyridamole 
(extended release 200 mg twice daily) to aspirin (50 mg daily) reduced serious vascular 
events by 22% (95% confidence interval [CI] 9-33%) in comparison with aspirin 
alone.5;18 The positive results of two meta-analyses on this comparison were based 
mainly on the results of ESPS 2, which was by far the largest trial included.19;20 
Subsequently, the European/Australasian Stroke Prevention in Reversible Ischemia Trial 
(ESPRIT)21 confirmed the results of ESPS 2; the hazard ratio for the primary outcome 
event (vascular death, recurrent stroke, myocardial infarction, or major bleeding 
complication) was 0.80 (95% CI 0.66-0.98).21 
We have updated the earlier meta-analysis based on individual patient data (IPD)20 with 
the inclusion of ESPRIT and aimed to identify patients who may benefit most from the 
combination of aspirin and dipyridamole. In particular, we wished to assess whether a 
patient’s baseline risk would modify the efficacy of combination therapy. 
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Methods 
Searching and selection 
The search strategy to identify all eligible randomized controlled trials on the 
effectiveness of dipyridamole in the secondary prevention after TIA or minor stroke of 
arterial origin has been described previously.20 We selected trials which compared, at a 
minimum, the combination therapy of aspirin and dipyridamole with aspirin alone. The 
principal investigators of each included trial shared individual patient data for use in the 
current analysis. 
 
Data abstraction 
Data from the different trials were merged into a single data set for analysis. This 
database contained information on demography (age, sex), qualifying event (TIA or 
stroke, clinical features of the event, findings on brain imaging), vascular risk profile 
(history by of hypertension, diabetes, ischemic heart disease or stroke and blood pressure 
at baseline), prescribed trial medication (dose of aspirin and formulation of dipyridamole) 
and the occurrence of serious events ((vascular) death, myocardial infarction or stroke) 
during the trial. On the basis of findings on brain imaging (CT or MRI) and clinical 
features, we classified patients as having small or large vessel disease. If a relevant 
ischemic lesion was detected with imaging, classification was based on the characteristics 
of this lesion. If no lesion was detected, we used clinical symptoms for classification as in 
previous studies.22;23 
 
Study characteristics 
The primary outcome event was the composite of death from all vascular causes, non-
fatal stroke and non-fatal myocardial infarction. Secondary outcome events were the 
composite of death from all vascular causes or non-fatal stroke, all death, death from 
vascular causes, fatal and non-fatal stroke, and fatal and non-fatal myocardial infarction. 
Prespecified subgroup analyses for the primary outcome event were performed according 
to age (<65 years vs. ≥65 years), sex (male vs. female), qualifying event (TIA vs. stroke), 
type of vessel disease in qualifying event (small vs. large), dose of aspirin (<75 mg vs. 
≥75 mg), formulation of dipyridamole (immediate vs. extended release), time between 
qualifying event and randomization (< 1 week vs 1 week-1 month vs 1-6 months) and 
history of hypertension, diabetes, stroke or ischemic heart disease. 
In addition we did a subgroup analysis according to baseline risk as assessed with two 
different risk models. The first model used three risk factors: age 65 years or older, stroke 
as a qualifying event and a history of hypertension; the risk of stroke increased with an 
increasing number of risk factors (0-3) in the previous IPD meta-analysis.20 The area 
under the receiver operator characteristics curve (AUC-ROC) for this model in the 
current data set was 0.59 (95% CI 0.57-0.60) The second model was developed with data 
from the Dutch TIA Trial (DTT), a secondary stroke prevention trial with a factorial 
design comparing two doses of aspirin, and atenolol, with placebo.24;25 We used those 
characteristics identified previously to be associated with new vascular events26 and that 
were available in the present dataset, resulting in a risk score: 0.532*sex (0: female, 1: 
male) + 0.037*age (years) + 0.757*diabetes (0: no, 1: yes) + 0.383*history of ischemic 
heart disease (0:no, 1: yes) + 0.007*systolic blood pressure (mm Hg); its AUC-ROC was 
0.62 (95% CI 0.60-0.64). Based on this risk score, patients were divided into 5 risk-
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quintiles. Subgroup analyses were performed based on the different risk groups from 
these two models. The numbers needed to treat were calculated for each subgroup. In 
Table 1 a cross-tabulation for the risk scores from the two models is shown to give an 
impression of the agreement of risk between the models. 
 
Table 1. Cross-tabulation for the risk scores from the two models used (both scores 
known for 5,967 patients) 
Risk score quintiles* Risk score based on 3 risk factors†; n of factors present 
 0 1 2 3 
1 237 594 365 2 
2 116 392 521 164 
3 58 273 556 310 
4 15 180 547 449 
5 2 81 469 636 
 
*: quintiles based on risk score calculated with formula: 0.532*sex (0: female, 1: male) 
+ 0.037*age (years) + 0.757*diabetes (0: no, 1: yes) + 0.383*history of ischemic heart 
disease (0: no, 1: yes) + 0.007*systolic blood pressure (mm Hg) 
†: risk factors: age 65 years or older, stroke as a qualifying event and a history of 
hypertension 
 
Quantitative data synthesis 
Data were analyzed according to the intention-to-treat principle. The occurrence of 
outcome events was compared between patients allocated to combined aspirin and 
dipyridamole versus patients allocated to aspirin in terms of the hazard ratio (HR, with 
95% CI), calculated with Cox proportional hazard modeling. To adjust for a possible 
heterogeneity between the trials we stratified the Cox model with trial as the stratification 
factor.27 All analyses were in duplicate performed, independently, by two investigators 
(PH, LG). 
Analyses were performed with Stata version 8 and SPSS version 12.0.02.  
 
Statement of responsibility 
The authors had full access to the data and take responsibility for its integrity. All authors 
have read and agree to the manuscript as written. The Corresponding Author has the right 
to grant on behalf of all authors and does grant on behalf of all authors, an exclusive 
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Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published 
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products to exploit all subsidiary rights, as set out in our licence.   
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Results 
Trial flow and study characteristics 
Five randomized controlled trials comparing the combination of aspirin and dipyridamole 
with aspirin alone in the secondary prevention after cerebral ischemia of arterial origin 
were identified (Figure 1).5;14-16;21 In  two trials, randomization was only done between 
combination therapy and aspirin alone;16;21 whereas the other trials also compared 
combination therapy with placebo,5;14;15 or dipyridamole alone.5 The dose of aspirin was 
fixed in four trials: 25 mg twice daily,5 300 mg three times daily,14 325 mg three times 
daily16 or 330 mg three times daily.15 In ESPRIT the dose of aspirin was left to the 
discretion of the treating physician, provided it was between 30 and 325 mg daily. The 
dose of dipyridamole was 50 mg three times daily14, 75 mg three15 or four16 times daily or 
200 mg twice daily.5;21 In three trials all patients used the immediate release formulation 
of dipyridamole,14-16 and in one trial all patients used the extended release formulation.5 
In ESPRIT the majority of patients (83%) used the extended release formulation and the 
remaining patients used the immediate release formulation.21 One trial only included 
patients with a TIA;16 the others also included patients with a minor stroke.5;14;15;21 The 
five trials included 3,800 patients allocated to combined aspirin and dipyridamole, and 
3,812 patients allocated to aspirin alone. Table 2 shows the baseline characteristics for the 
different trials and for the combined data. Apart from the differences mentioned above 
(dose of aspirin, formulation of dipyridamole and type of qualifying event), the main 
difference between the samples was that the mean age was higher in ESPS 2 (mean age 
67 versus 62-63 in the other trials) and the fact that in the Toulouse trial there were more 
males included (more than 80% versus less than 70% in the others). In total, almost two-
thirds of patients were male with a mean age of 65 years. In the majority the qualifying 
event was a stroke. There were no major differences in the prevalence of vascular risk 
factors between the different trials. The mean length of follow-up was 2.6 years (range 0-
8.21 years). 
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Table 2. Trial characteristics for included trials 
*: mean (SD), FU: duration of follow-up (months), Trt.: allocated treatment, N: number of patients, QE: stroke as qualifying event, 
Stroke: stroke before qualifying event, HT: history of hypertension, SBP: systolic blood pressure, DBP: diastolic blood pressure, IHD: 
history of ischemic heart disease, DM: history of diabetes mellitus, AD: aspirin plus dipyridamole, A: aspirin, †: total limited to the 
trials with data for this characteristic 
Trial  
Year 
FU Trt. N Male (%) Age* QE (%) Stroke (%) HT (%) SBP* DBP* IHD DM 
Toulouse 
198214 
36-72 AD 
A 
  137 
  147 
  112 (82) 
  126 (86) 
62 (10) 
62   (9) 
   81 (60) 
   92 (63) 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
AICLA 
198315 
36 AD 
A 
  202 
  198 
  146 (72) 
  131 (66) 
63 (10) 
63 (10) 
 169 (84) 
   68 (85) 
- 
- 
  119 (59) 
  129 (65) 
149 (20) 
150 (21) 
90 (10) 
90 (12) 
- 
- 
  51 (25) 
  44 (22) 
ACSSG 
198516 
24-60 AD 
A 
  448 
  442 
  306 (68) 
  288 (65) 
63 (10) 
63 (10) 
     0 
     0 
- 
- 
  214 (48) 
  205 (46) 
- 
- 
- 
- 
- 
- 
  70 (16) 
  49 (11) 
ESPS 2 
19965 
24 AD 
A 
1650 
1649 
  956 (58) 
  956 (58) 
67 (11) 
67 (11) 
1246 (76) 
1257 (76) 
439 (27) 
464 (28) 
  979 (60) 
  983 (60) 
150 (22) 
151 (21) 
85 (12) 
86 (11) 
573 (35) 
571 (35) 
254 (15) 
240 (15) 
ESPRIT 
200621 
mean 
42 
AD 
A 
1363 
1376 
  897 (66) 
  892 (65) 
63 (11) 
63 (11) 
  895 (66) 
  921 (67) 
159 (12) 
155 (11) 
  814 (60) 
  817 (59) 
152 (24) 
152 (23) 
86 (12) 
86 (12) 
179 (13) 
177 (13) 
260 (19) 
252 (18) 
  
 
          
Total 31 AD 
A 
3800 
3812 
2417 (64) 
2393 (63) 
65 (11) 
65 (11) 
2391 (63) 
2438 (64) 
598 (20)† 
619 (21)† 
2126 (58)† 
2134 (58)† 
151 (23)† 
151 (22)† 
86 (12)† 
86 (12)† 
749 (25)† 
748 (25)† 
635 (17)† 
585 (16)† 
 o
n
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Quantitative data synthesis 
In the combined aspirin and dipyridamole group 475 patients (12.5%) had a primary 
outcome event, compared with 579 patients (15.2%) in the aspirin group, resulting in an 
adjusted HR of 0.82 (95% CI 0.72-0.92) (Table 3). The adjusted HR for the composite 
event of death from vascular cause or non-fatal stroke was 0.81 (95% CI 0.72-0.92), that 
for vascular death 0.96 (95% CI 0.78-1.18) and for recurrent stroke 0.78 (95% CI 0.68-
0.90). The number needed to treat (1/absolute risk reduction*100) with aspirin plus 
dipyridamole instead of aspirin alone to prevent one serious vascular event to happen is 
100 per year. Figure 2 shows the time-to-event curve for the primary outcome event. 
 
Table 3. Occurrence of outcome events, according to treatment 
 ASA+DIP 
n = 3800 
ASA 
n = 3812 
HR 95% CI 
Person-years of 
observation 
9441 9396   
Vascular death, non-
fatal stroke or non-fatal 
myocardial infarction 
475 (12.5%) 579 (15.2%) 0.82 0.72-0.92 
Vascular death or non-
fatal stroke 
434 528 0.81 0.72-0.92 
All death 358 360 1.01 0.87-1.17 
Vascular death 175 187 0.96 0.78-1.18 
Recurrent stroke 341 429 0.78 0.68-0.90 
Myocardial infarction 81 87 0.94 0.69-1.27 
ASA+DIP: aspirin and dipyridamole, ASA: aspirin, MI: myocardial infarction   
HR: hazard ratio, adjusted for trial; CI = confidence interval 
 
Figure 3 shows the results of the subgroup analyses according to age, sex, qualifying 
event, hypertension, diabetes, stroke, ischemic heart disease, dose of aspirin, type of 
vessel disease, formulation of dipyridamole and interval between qualifying event and 
randomization for the primary outcome event. No major differences between the 
subgroups were found (smallest p value for interaction 0.14). The only slight differences 
in the estimated hazard ratios for the subgroups confirm the superior efficacy of aspirin 
plus dipyridamole in all groups. Figure 4 shows the subgroup analyses according to the 
number of risk factors present at baseline (known for 7,302 patients, panel A) and 
according to the risk score derived from the DTT-risk model (known for 5,989 patients, 
panel B). The HRs were broadly similar in all risk groups and not different from the 
overall HR (smallest p value for interaction 0.11). The numbers needed to treat with 
dipyridamole and aspirin instead of aspirin alone to prevent one major vascular event per 
year are shown as well; no major differences were found here either. 
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Discussion 
This individual patient data meta-analysis confirms that the combination of aspirin and 
dipyridamole is more effective than aspirin alone in secondary vascular prevention after 
TIA or minor stroke from arterial origin. From figure 2 we can conclude that the 
advantage of the combination therapy of aspirin plus dipyridamole starts early on and 
remains present over time. Importantly, analyses in prognostic subgroups, including age, 
sex and vascular history, found no differential effects between groups of patients whereas 
currently there may be a selection of patients who receive dipyridamole in addition to 
aspirin. Quantitatively, combined aspirin and dipyridamole reduce vascular events by 
18%, and stroke by 22%, as compared with aspirin alone, results which do not differ 
materially from earlier meta-analyses,19-21 In contrast, dual antiplatelet therapy had no 
advantage over aspirin in preventing total death, vascular death, or myocardial infarction; 
importantly, the combination of aspirin and dipyridamole did not increase the incidence 
of myocardial infarction. 
The number needed to treat found in this meta-analysis is 100 per year, which is about the 
same as the number needed to treat for aspirin versus placebo. Whether this NNT is cost-
effective for aspirin plus dipyridamole should be formally assessed in a cost-effectiveness 
analysis.  
The risk models we used did not have a strong discriminatory ability with regard to 
prediction of major vascular events, as is obvious from the AU ROCs (0.59 and 0.62 
respectively). Unfortunately, there are no stronger prediction models for vascular events 
after a TIA or minor stroke.28 Moreover, we could only use those variables that were 
available in the included trials. 
 
Previous subgroup analyses in ESPS 2 suggested that the relative efficacy for 
combination therapy was greater in patients at high risk of recurrence than those at lower 
risk.29;30 In our larger individual patient data meta-analysis, in contrast, we found that 
relative efficacy for vascular events was not related to the estimated baseline risk. 
Moreover, the numbers needed to treat varied between the different risk groups, but there 
was no indication that these numbers were higher in low risk patients. The independence 
of relative risk reduction from baseline risk is important since the risk of recurrence has 
fallen with time in patients randomized to aspirin (overall, 6.1% per year versus 4.3% per 
year in ESPRIT), this presumably reflecting improved non-antiplatelet prophylaxis. 
The main difference between the five trials was the prescribed trial medication. Aspirin 
doses varied reflecting historical and geographical variations in practice. Since lower 
doses of aspirin (30-75 mg daily) are no less effective at preventing vascular recurrence 
than higher doses,2;24 this variation is unlikely to have influenced the results. Similarly, 
the dose and formulation of dipyridamole varied between the trials; older studies used 
short acting (immediate release) dipyridamole give 3-4 times per day 14-16 whereas all 
patients in ESPS 2 and most (83%) in ESPRIT received extended release dipyridamole 
twice daily.5;21 This difference might explain, in part, the difference seen in efficacy 
between older and newer trials with dipyridamole. However, our subgroup analyses do 
not show any differences in efficacy of aspirin and dipyridamole between different doses 
of aspirin or different formulations of dipyridamole. 
The results of meta-analyses may be confounded if data from unpublished trials are not 
available for inclusion; notably, these trials are more likely to be neutral or negative in 
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outcome leading to publication bias. Missing trials have never been reported to us 
following our previous meta-analyses 19;20 so it is very unlikely that any medium-sized to 
large trials are missing here. However, data on risk factors were not available for all five 
trials so the subgroup analyses involve fewer patients for some analyses. Nevertheless, 
meta-analysis allows the total evidence to be assessed and the use of individual patient 
data, as here, is superior to the use of summary group data.31 
The superiority of combination aspirin and dipyridamole over aspirin alone in secondary 
vascular prevention after TIA or stroke is now well supported. The hazard ratio found in 
this individual patient data meta-analysis is consistent with the two largest clinical trials 
and does not appear to differ in subgroups of patients. Combination therapy with aspirin 
and dipyridamole should be preferred over aspirin alone in all patients after a TIA or 
minor stroke of presumed arterial origin, as supported by several national guidelines. 
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Figure legends 
 
Figure 1. Trial flow 
 
Figure 2. Time-to-event curve for the primary outcome event 
 
Figure 3. Subgroup analyses according to risk factors  
a: number of trials for which the characteristic is known; b: number of patients in 
subgroup; c: stroke before qualifying event; d: history of ischemic heart disease; e: 
qualifying event 
 
Figure 4. Subgroup analyses based on risk groups; A: risk groups based on presence of 3 
risk factors; B: groups based on DTT-risk model 
*: risk on a major vascular event (vascular death, nonfatal stroke or nonfatal myocardial 
infarction) per year; NNT: numbers needed to treat with aspirin and dipyridamole 
instead of with aspirin alone to prevent one major vascular event per year; HR: hazard 
ratio
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Figure 1. Trial flow 
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Figure 2. Time-to-event curve for the primary outcome event 
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Figure 3. Subgroup analyses according to risk factors  
a: number of trials for which the characteristic is known; b: number of patients in 
subgroup; c: stroke before qualifying event; d: history of ischemic heart disease; e: 
qualifying event 
 
 
 
  
     2         1774         0.71 (0.55, 0.93) 
                 0,5    favors aspirin plus dipyridamole        1     favors aspirin    2 
Age 
Sex 
Qualifying event 
Hypertension
Diabetes 
Stroke
c 
 Subgroup        trials
a
   patients
b
HR(95% CI) 
yes 
yes 
no 
no 
yes 
no 
stroke 
TIA 
female 
male 
≥ 65 years 
< 65 years 
IHD
d 
Aspirin dose
Formulation 
yes 
no 
< 75 mg 
≥ 75 mg 
immediate 
extended dipyridamole
 
Type of  vessel
small
large 
Interval QE
e
 - 
randomisation 
< 1 week 
1 week-1 month 
1-6 months 
      2 1497 0.88 (0.70, 1.10) 
      2 4501 0.73 (0.61, 0.87) 
      2 1217 0.65 (0.50, 0.85) 
      2 4786 0.83 (0.70, 0.98) 
      4 1220 0.79 (0.61, 1.02) 
      4 6108 0.81 (0.71, 0.94) 
      4 4260 0.79 (0.68, 0.92) 
      4 3046 0.84 (0.68, 1.03) 
      5 4829 0.81 (0.69, 0.93) 
 
      5 2779 0.85 (0.68, 1.05) 
      5 2802 0.91 (0.74, 1.12) 
      5 4810 0.77 (0.66, 0.89) 
      5 4067 0.84 (0.73, 0.98) 
      5 3545 0.75 (0.61, 0.93) 
      5 4624 0.78 (0.67, 0.92) 
      5 2988 0.87 (0.72, 1.05) 
      5 2002 0.89 (0.71, 1.11) 
      5 5610 0.79 (0.68, 0.91) 
     2         2645         0.77 (0.62, 0.96) 
     2           839         0.87 (0.63, 1.23) 
     2         2065        0.85 (0.68,1.07) 
     2         3093        0.70 (0.57, 0.86) 
 on 7 October 2008 jnnp.bmj.comDownloaded from 
2Figure 4. Subgroup analyses based on risk groups; A: risk groups based on presence of 3 
risk factors; B: groups based on DTT-risk model 
*: risk on a major vascular event (vascular death, nonfatal stroke or nonfatal myocardial 
infarction) per year; NNT: numbers needed to treat with aspirin and dipyridamole instead 
of with aspirin alone to prevent one major vascular event per year; HR: hazard ratio 
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